Obsidian Therapeutics, Inc. (OBX) Stock Forecast
OBX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $39.00 average of analyst targets
- Upside to target
- +231.4% from the latest close
- Next earnings
- —
- 52-week range
- $11.77 – $35.00
OBX analyst ratings
5 analystsNumber of analysts at each rating.
OBX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OBX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.47 | −$0.38 | — | — | 3 |
| Current fiscal year (2026) | −$1.82 | −$2.62 | −$1.00 | −$2,057.27 | +99.9% | 3 |
| Next fiscal year (2027) | −$2.79 | −$3.85 | −$2.13 | −$1.82 | −53.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OBX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
OBX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OBX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.59 | −$0.44 | −$0.42 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | −$2.48 | −$2.23 | −$1.82 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$2.99 | −$2.79 | −$2.79 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OBX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OBX beat in 1 of 1.
What analysts expect from OBX
5 analysts cover Obsidian Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $39.00, 231.4% above the latest close of $11.77. Analysts expect earnings of −$1.82 per share for 2026, +99.9% from a year earlier. For 2027 the average estimate is −$2.79 per share. Obsidian Therapeutics beat the EPS estimate in 1 of the last 1 quarters.
Related: OBX income statement, OBX key metrics, OBX chart. See the OBX stock overview for the latest quote and news.
OBX forecast FAQ
What is Obsidian Therapeutics's price target?
The average analyst price target for Obsidian Therapeutics is $39.00, 231.4% above the latest close of $11.77.
Is Obsidian Therapeutics a buy, hold or sell?
Of 5 analysts covering Obsidian Therapeutics, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Obsidian Therapeutics's EPS forecast?
Analysts forecast −$1.82 per share for 2026 (range −$2.62 to −$1.00); for 2027 the estimate is −$2.79.
Does Obsidian Therapeutics usually beat earnings estimates?
Obsidian Therapeutics reported EPS at or above the analyst estimate in 1 of the last 1 quarters.